基质佐剂

Q1 Pharmacology, Toxicology and Pharmaceutics
Pilar Garcia-Vello , Immacolata Speciale , Fabrizio Chiodo , Antonio Molinaro , Cristina De Castro
{"title":"基质佐剂","authors":"Pilar Garcia-Vello ,&nbsp;Immacolata Speciale ,&nbsp;Fabrizio Chiodo ,&nbsp;Antonio Molinaro ,&nbsp;Cristina De Castro","doi":"10.1016/j.ddtec.2020.09.005","DOIUrl":null,"url":null,"abstract":"<div><p>Carbohydrate adjuvants are safe and biocompatible compounds usable as sustained delivery systems and stimulants of ongoing humoral and cellular immune responses, being especially suitable for the development of vaccines against intracellular pathogens where alum is useless. The development of new adjuvants is difficult and expensive, however, in the last two years, seven new carbohydrate-based adjuvants have been patented, also there are twelve ongoing clinical trials of vaccines that contain carbohydrate-based adjuvants, as well as numerous publications on their mechanism of action and safety. More research is necessary to improve the existent adjuvants and develop innovative ones.</p></div>","PeriodicalId":36012,"journal":{"name":"Drug Discovery Today: Technologies","volume":null,"pages":null},"PeriodicalIF":0.0000,"publicationDate":"2020-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1016/j.ddtec.2020.09.005","citationCount":"19","resultStr":"{\"title\":\"Carbohydrate-based adjuvants\",\"authors\":\"Pilar Garcia-Vello ,&nbsp;Immacolata Speciale ,&nbsp;Fabrizio Chiodo ,&nbsp;Antonio Molinaro ,&nbsp;Cristina De Castro\",\"doi\":\"10.1016/j.ddtec.2020.09.005\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<div><p>Carbohydrate adjuvants are safe and biocompatible compounds usable as sustained delivery systems and stimulants of ongoing humoral and cellular immune responses, being especially suitable for the development of vaccines against intracellular pathogens where alum is useless. The development of new adjuvants is difficult and expensive, however, in the last two years, seven new carbohydrate-based adjuvants have been patented, also there are twelve ongoing clinical trials of vaccines that contain carbohydrate-based adjuvants, as well as numerous publications on their mechanism of action and safety. More research is necessary to improve the existent adjuvants and develop innovative ones.</p></div>\",\"PeriodicalId\":36012,\"journal\":{\"name\":\"Drug Discovery Today: Technologies\",\"volume\":null,\"pages\":null},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2020-12-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://sci-hub-pdf.com/10.1016/j.ddtec.2020.09.005\",\"citationCount\":\"19\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Drug Discovery Today: Technologies\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://www.sciencedirect.com/science/article/pii/S1740674920300172\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q1\",\"JCRName\":\"Pharmacology, Toxicology and Pharmaceutics\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Drug Discovery Today: Technologies","FirstCategoryId":"1085","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S1740674920300172","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"Pharmacology, Toxicology and Pharmaceutics","Score":null,"Total":0}
引用次数: 19

摘要

碳水化合物佐剂是安全且具有生物相容性的化合物,可作为持续递送系统和正在进行的体液和细胞免疫反应的兴奋剂,特别适用于开发针对细胞内病原体的疫苗,其中明矾是无用的。新佐剂的开发是困难和昂贵的,然而,在过去的两年中,七种新的碳水化合物佐剂已经获得专利,还有12种含有碳水化合物佐剂的疫苗正在进行临床试验,以及许多关于其作用机制和安全性的出版物。对现有佐剂进行改进和开发新型佐剂还需要进一步的研究。
本文章由计算机程序翻译,如有差异,请以英文原文为准。

Carbohydrate-based adjuvants

Carbohydrate-based adjuvants

Carbohydrate adjuvants are safe and biocompatible compounds usable as sustained delivery systems and stimulants of ongoing humoral and cellular immune responses, being especially suitable for the development of vaccines against intracellular pathogens where alum is useless. The development of new adjuvants is difficult and expensive, however, in the last two years, seven new carbohydrate-based adjuvants have been patented, also there are twelve ongoing clinical trials of vaccines that contain carbohydrate-based adjuvants, as well as numerous publications on their mechanism of action and safety. More research is necessary to improve the existent adjuvants and develop innovative ones.

求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
Drug Discovery Today: Technologies
Drug Discovery Today: Technologies Pharmacology, Toxicology and Pharmaceutics-Drug Discovery
自引率
0.00%
发文量
0
期刊介绍: Discovery Today: Technologies compares different technological tools and techniques used from the discovery of new drug targets through to the launch of new medicines.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信